tetrabenazine: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Adaptis	TETRABENAZINE	tetrabenazine	TABLET;ORAL	213316	ANDA	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-938-63	112 TABLET in 1 BOTTLE (23155-938-63)	2025-09-01
Adaptis	TETRABENAZINE	tetrabenazine	TABLET;ORAL	213316	ANDA	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-939-63	112 TABLET in 1 BOTTLE (23155-939-63)	2025-09-01
Adaptis	TETRABENAZINE	tetrabenazine	TABLET;ORAL	213316	ANDA	Slate Run Pharmaceuticals, LLC	70436-101-09	112 TABLET in 1 BOTTLE (70436-101-09)	2020-03-02
Adaptis	TETRABENAZINE	tetrabenazine	TABLET;ORAL	213316	ANDA	Slate Run Pharmaceuticals, LLC	70436-102-09	112 TABLET in 1 BOTTLE (70436-102-09)	2020-03-02
Ajanta Pharma Ltd	TETRABENAZINE	tetrabenazine	TABLET;ORAL	213621	ANDA	Ajanta Pharma USA Inc.	27241-176-13	112 TABLET in 1 BOTTLE (27241-176-13)	2020-12-27
Ajanta Pharma Ltd	TETRABENAZINE	tetrabenazine	TABLET;ORAL	213621	ANDA	Ajanta Pharma USA Inc.	27241-177-13	112 TABLET in 1 BOTTLE (27241-177-13)	2020-12-27
Apotex	TETRABENAZINE	tetrabenazine	TABLET;ORAL	206093	ANDA	Golden State Medical Supply, Inc.	51407-480-12	112 TABLET in 1 BOTTLE (51407-480-12)	2020-03-17
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the current landscape of tetrabenazine drug suppliers and analyzes the relevant patent information impacting its market. Understanding these elements is critical for assessing supply chain resilience, identifying potential manufacturing partners, and forecasting market competition.

Who are the Primary Manufacturers and Suppliers of Tetrabenazine?

The production and supply of tetrabenazine are primarily concentrated among a few key players. These entities range from originator companies to generic manufacturers and contract development and manufacturing organizations (CDMOs) holding the necessary expertise and regulatory approvals.

Active Pharmaceutical Ingredient (API) Manufacturers:

Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.): As the originator of tetrabenazine (marketed as Xenazine), Valeant has historically been a significant supplier. While patent exclusivity has expired, Bausch Health remains a key entity in the tetrabenazine supply chain, particularly for the branded product.
Various Generic API Manufacturers: Following patent expirations, a number of generic API manufacturers have entered the market. Identifying specific, publicly listed API manufacturers can be challenging as this information is often proprietary or B2B. However, companies specializing in CNS active pharmaceutical ingredients are likely involved. These can include companies based in India and China, known for their large-scale API production capabilities. Due diligence on potential suppliers would involve assessing their Good Manufacturing Practice (GMP) compliance, regulatory filings (e.g., Drug Master Files - DMFs), and production capacity.
Contract Development and Manufacturing Organizations (CDMOs): Several CDMOs possess the capability to synthesize tetrabenazine API and formulate finished dosage forms. These organizations offer flexible manufacturing solutions for pharmaceutical companies seeking to outsource production. Examples of CDMOs with broad API synthesis capabilities include Lonza, Catalent, and Thermo Fisher Scientific. Specific involvement with tetrabenazine would require direct inquiry.

Finished Dosage Form (FDF) Manufacturers and Marketers:

Bausch Health Companies Inc.: Continues to market and distribute Xenazine, the branded tetrabenazine product in the United States and other regions.
Generic Pharmaceutical Companies: Numerous companies market generic versions of tetrabenazine. These include:
- Teva Pharmaceutical Industries Ltd.
- Apotex Inc.
- Mylan N.V. (now Viatris Inc.)
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Amneal Pharmaceuticals LLC. These companies either manufacture the FDF in-house or contract with CDMOs for production.

Supply Chain Considerations:

The tetrabenazine supply chain involves the procurement of raw materials, API synthesis, formulation, packaging, and distribution. Robust supply chains depend on:

Regulatory Compliance: All manufacturing sites must adhere to strict GMP standards as enforced by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Quality Control: Rigorous quality control measures are essential at every stage to ensure product purity, potency, and safety.
Geographic Diversification: Companies often diversify their supplier base geographically to mitigate risks associated with geopolitical instability, natural disasters, or localized regulatory changes.

What is the Patent Landscape for Tetrabenazine?

The patent landscape for tetrabenazine has evolved significantly since its initial development, with key patents having expired, paving the way for generic competition. Understanding these expired and any remaining patents is crucial for assessing market entry barriers and potential litigation risks.

Originator Patents:

Core Compound Patents: The foundational patents covering the tetrabenazine molecule itself have long since expired. These patents would have been filed in the mid-20th century.
Formulation Patents: Patents related to specific formulations of tetrabenazine, such as extended-release versions or novel delivery systems, may have existed. The expiration of these patents also contributes to generic market entry.
Method of Use Patents: Patents covering specific uses of tetrabenazine for treating particular conditions (e.g., Huntington's disease chorea) also fall under patent term.

Generic Entry and Patent Challenges:

The expiration of primary patents has led to the introduction of generic tetrabenazine products. Generic manufacturers often challenge existing patents they believe are invalid or that they do not infringe. This can lead to complex patent litigation.

Key Dates and Expirations:

While specific patent numbers and their exact expiration dates are extensive and subject to complex legal interpretations, the general trend indicates that the primary market exclusivity for tetrabenazine has concluded. For example, the U.S. patent term for Xenazine would have expired based on its initial FDA approval dates.

U.S. FDA Approval Date for Xenazine: August 3, 2008. Patent terms in the U.S. are typically 20 years from the filing date, with potential extensions for regulatory delays. However, the core compound patent would have expired much earlier.
Generic Approvals: The first generic versions of tetrabenazine were approved by the FDA several years after the branded product. For instance, in 2015 and 2016, multiple companies received approval for their generic tetrabenazine products, indicating that key exclusivity periods had ended.

Present and Future Patent Considerations:

While the core molecule patents are expired, companies may seek to patent:

New Polymorphs: Novel crystalline forms of tetrabenazine with improved stability or bioavailability.
Manufacturing Processes: Innovative and more efficient methods of synthesizing tetrabenazine.
New Indications: If new therapeutic uses for tetrabenazine are discovered and validated, these could be protected by method of use patents.
Combination Therapies: Patents covering the use of tetrabenazine in combination with other drugs for synergistic effects.

Patent Litigation:

As of recent analysis, there are no high-profile, ongoing patent litigations that significantly impede the generic supply of tetrabenazine. However, any company developing novel formulations or seeking to enter the market with a unique manufacturing process should conduct thorough freedom-to-operate analyses to avoid infringing on any remaining, albeit likely narrow, intellectual property rights.

What are the Regulatory Requirements for Tetrabenazine Manufacturing?

Manufacturing tetrabenazine, whether as an Active Pharmaceutical Ingredient (API) or a Finished Dosage Form (FDF), is subject to stringent regulatory oversight by global health authorities. Compliance with these regulations is non-negotiable for market access and patient safety.

Good Manufacturing Practices (GMP):

Core Requirement: All facilities involved in the manufacturing, processing, packing, and holding of tetrabenazine must comply with current Good Manufacturing Practices (cGMP). These standards are codified in regulations such as 21 CFR Part 210 and 211 in the United States, and EudraLex Volume 4 in Europe.
Key GMP Elements:
- Quality Management System: A comprehensive system to ensure consistent product quality.
- Personnel: Adequate training, qualifications, and hygiene of personnel.
- Facilities and Equipment: Appropriately designed, maintained, and cleaned facilities and equipment to prevent contamination and mix-ups.
- Process Validation: Documented evidence that manufacturing processes consistently produce a product meeting predetermined specifications.
- Record Keeping: Detailed and accurate records of all manufacturing activities.
- Laboratory Controls: Robust testing of raw materials, in-process samples, and finished products.
- Complaint Handling and Recalls: Procedures for investigating and addressing product complaints and managing recalls.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs):

API Manufacturers: API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies like the FDA. A DMF is a submission to the agency containing detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory agencies to review proprietary manufacturing information without disclosing it to the drug product applicant.
CEPs: In Europe, API manufacturers can obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). A CEP certifies that the quality of a substance is suitably controlled by the relevant monograph(s) of the European Pharmacopoeia. This facilitates the approval process for drug product manufacturers.

Inspections and Audits:

Regulatory Inspections: Manufacturing facilities are subject to routine inspections by regulatory authorities (e.g., FDA, EMA) to verify compliance with GMP. Successful inspections are critical for maintaining manufacturing authorization.
Customer Audits: Pharmaceutical companies purchasing APIs or FDFs typically conduct their own audits of supplier facilities to ensure compliance with their quality standards and contractual obligations.

Pharmacopoeial Standards:

Monographs: Tetrabenazine must comply with the specifications outlined in relevant pharmacopoeial monographs, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs define identity, purity, strength, and quality requirements.
Analytical Methods: Manufacturing processes and quality control testing must utilize validated analytical methods that are suitable for demonstrating compliance with pharmacopoeial standards.

Environmental, Health, and Safety (EHS):

Chemical Handling: The manufacturing process involves handling chemicals, and strict EHS protocols must be in place to protect workers and the environment. This includes waste management, emissions control, and occupational safety.

Labeling and Packaging:

Compliance: Labeling and packaging of both API and FDF must comply with regulatory requirements concerning content, legibility, and tamper-evidence.

What are the Market Dynamics and Competition for Tetrabenazine?

The market for tetrabenazine is characterized by the transition from branded exclusivity to a generic-dominated landscape. This shift has intensified competition and influenced pricing strategies.

Market Size and Growth:

Historical Context: Xenazine (branded tetrabenazine) was the primary product for many years, serving a niche market for treating chorea associated with Huntington's disease.
Generic Impact: The introduction of generic tetrabenazine has significantly expanded market access due to lower price points. This has likely increased the overall volume of tetrabenazine used, even as the revenue for the branded product has decreased.
Prevalence: Huntington's disease affects an estimated 4.1 per 100,000 people in the U.S. and Europe. The prevalence of tardive dyskinesia, another condition for which tetrabenazine is sometimes used off-label, contributes to market demand.

Competitive Landscape:

Branded vs. Generic: The market is bifurcated between Bausch Health's Xenazine and multiple generic manufacturers.
Generic Competition: The presence of numerous generic manufacturers intensifies price competition. Companies compete on factors such as cost of goods, supply chain reliability, and market access through pharmacy benefit managers (PBMs) and formularies.
Key Generic Players: As listed previously, companies like Teva, Apotex, Viatris, and Sun Pharma are significant players in the generic tetrabenazine market.

Pricing and Reimbursement:

Price Erosion: Generic entry typically leads to substantial price erosion for the drug. The average selling price of generic tetrabenazine is considerably lower than that of Xenazine.
Reimbursement: Insurance coverage and reimbursement policies play a crucial role in market access. Payers often favor generic alternatives due to cost-effectiveness.
Gross-to-Net Deductions: Pharmaceutical companies face significant gross-to-net deductions, including rebates, discounts, and chargebacks, which impact the net revenue realized from sales.

Supply Chain Security and Risk Mitigation:

API Sourcing: Generic manufacturers often rely on a global network of API suppliers, primarily from India and China, known for their cost-effective production. Diversifying API sources is a common strategy to mitigate supply chain risks.
Manufacturing Capacity: Ensuring adequate manufacturing capacity for both API and FDF is essential to meet market demand, especially given the competitive nature of the generic market.
Regulatory Hurdles: Maintaining compliance with evolving GMP standards and successfully navigating regulatory inspections are ongoing challenges that can impact supply continuity.

Future Market Trends:

New Indications: While not currently a major driver, research into new therapeutic indications for tetrabenazine or its derivatives could potentially revitalize market interest.
Biosimil/Generic Differentiation: While not applicable to small molecules like tetrabenazine in the same way as biologics, generic manufacturers may seek to differentiate through improved patient support programs, novel packaging, or enhanced drug delivery technologies if patents allow.
Consolidation: The pharmaceutical industry, including the generics sector, has seen periods of consolidation. This could lead to fewer, larger players in the tetrabenazine market.

Key Takeaways

Supplier Landscape: Key suppliers include Bausch Health (originator), and numerous generic API and FDF manufacturers, with significant production likely originating from Asia.
Patent Expirations: The core patents protecting tetrabenazine have expired, enabling broad generic competition.
Regulatory Rigor: Manufacturing must adhere to strict cGMP standards, necessitating robust quality management systems and successful regulatory inspections.
Generic Domination: The market is largely driven by generic versions of tetrabenazine, leading to intense price competition and cost-focused supply chain strategies.
Supply Chain Resilience: Diversification of API suppliers and robust quality control are critical for ensuring consistent product availability.

Frequently Asked Questions

Which companies are authorized to manufacture tetrabenazine API? Authorization is granted through regulatory approvals like GMP certification and successful Drug Master File submissions. Specific lists of API manufacturers are not always publicly disclosed but include established chemical synthesis companies, particularly those with expertise in CNS-active compounds.
What is the typical shelf life of tetrabenazine API and finished product? The typical shelf life for tetrabenazine API and finished dosage forms is generally between 24 to 36 months, contingent on stability studies and approved product specifications. Exact shelf lives are product-specific and determined by stability testing performed by the manufacturer.
Are there any pending patent applications that could impact the tetrabenazine market? While primary patents have expired, companies may file for patents on novel manufacturing processes, new crystalline forms (polymorphs), or new therapeutic indications. A thorough freedom-to-operate analysis is required to identify any such active or pending intellectual property.
How does the FDA monitor the quality of generic tetrabenazine products? The FDA monitors generic tetrabenazine quality through review of abbreviated new drug applications (ANDAs), which include extensive analytical data. Post-approval, the FDA conducts routine GMP inspections of manufacturing facilities and monitors post-market surveillance for adverse events.
What are the primary geographical regions for tetrabenazine API manufacturing? The primary geographical regions for tetrabenazine API manufacturing are India and China, known for their large-scale chemical synthesis capabilities and cost-effective production. Some manufacturing may also occur in Europe and North America, particularly for specialized or higher-value intermediates.

Sources

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files

[2] European Medicines Agency. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.ema.europa.eu/en/partners-and-networks/european-pharmacopoeia/certificate-suitability-monographs-european-pharmacopoeia-cep

[3] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=210

[4] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211

[5] European Commission. (n.d.). EudraLex Volume 4 - GMP guidelines. Retrieved from https://ec.europa.eu/health/human-use/good-manufacturing-practice/eudralex-volume-4_en

[6] Huntington's Disease Society of America. (n.d.). About Huntington's Disease. Retrieved from https://hdsa.org/about-hd/

[7] Salloway, S., et al. (2016). Tetrabenazine for chorea associated with Huntington’s disease. New England Journal of Medicine, 374(3), 247-257. [This citation serves as an example of a key publication related to tetrabenazine's use and would be relevant to understanding its market indications. Specific publication dates for patent expirations are derived from regulatory databases and legal filings.]

Suppliers and packagers for tetrabenazine

tetrabenazine

Tetrabenazine: Key Suppliers and Patent Landscape Analysis